Page last updated: 2024-11-06

prulifloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Prulifloxacin is a synthetic antibacterial drug belonging to the fluoroquinolone class. It exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria, including those resistant to other antibiotics. Its mechanism of action involves inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and repair. Prulifloxacin is particularly effective against Pseudomonas aeruginosa, a common opportunistic pathogen, and is often used for treating infections associated with cystic fibrosis. The drug's importance lies in its ability to combat antibiotic-resistant strains, contributing to the fight against emerging bacterial infections. Research into prulifloxacin focuses on understanding its pharmacokinetic properties, evaluating its efficacy in various infections, and exploring its potential for overcoming bacterial resistance mechanisms.'
```

prulifloxacin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65947
CHEMBL ID422648
CHEBI ID32071
SCHEMBL ID1650794
MeSH IDM0200389

Synonyms (68)

Synonym
AC-2012
AKOS005559236
opt-99
prulifloxacin
pruvel
quisnon
nad-441a
sword
nm-441
123447-62-1
NCGC00164615-01
1h,4h-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-
ccris 7686
(+-)-7-(4-((z)-2,3-dihydroxy-2-butenyl)-1-piperazinyl)-6-fluoro-1-methyl-4-oxo-1h,4h-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid, cyclic carbonate
prulifloxacin [inn]
nm 441
nm441
nsc-759833
CHEMBL422648
6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
FT-0651733
6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-4-ium-1-yl]-4-oxo-1h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylate
STK626148
6-fluoro-1-methyl-7-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl}-4-oxo-4h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
j42298iesw ,
unii-j42298iesw
nsc 759833
tox21_112235
cas-123447-62-1
dtxsid0046480 ,
dtxcid8026480
6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
NCGC00164615-03
S2071
prulifloxacin [jan]
prulifloxacin [mi]
prulifloxacin [mart.]
prulifloxacin [who-dd]
BBL034010
HY-B0024
NCGC00164615-02
tox21_112235_1
SCHEMBL1650794
PWNMXPDKBYZCOO-UHFFFAOYSA-N
smr000046722
MLS006011767
Q-101929
prulifloxacin, antibiotic for culture media use only
P2058
prulifloxacin (hydrochloride)
mfcd00864847
sr-01000872596
SR-01000872596-1
CHEBI:32071
prulifloxacin, >=98% (perchloric acid titration)
6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1h,4h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
DB11892
Q3924793
F20576
AS-13607
BCP12727
BRD-A92341659-001-01-6
SB18983
1h,4h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-
af 3012
prulifloxacin (nm441, af 3013)
prulifloxacin 100 microg/ml in acetonitrile
nm441;af 3013

Research Excerpts

Overview

Prulifloxacin is a new fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and -negative bacteria. It is approved in several European countries for the treatment of lower urinary tract infections and exacerbations of chronic bronchitis.

ExcerptReferenceRelevance
"Prulifloxacin is a fluoroquinolone antibiotic that has been approved in several European countries for the treatment of lower urinary tract infections and exacerbations of chronic bronchitis. "( Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections.
Falagas, ME; Polyzos, KA; Rafailidis, PI; Sgouros, K, 2011
)
3.25
"Prulifloxacin is a promising fluoroquinolone antibiotic. "( Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
Chen, Y; Huang, W; Li, Q; Lu, G; Lv, X; Sun, Y; Wu, G; Wu, X; Wu, Y; Yang, H; Zhang, G, 2012
)
3.26
"Prulifloxacin is a new fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and -negative bacteria."( Prulifloxacin: a new antibacterial fluoroquinolone.
Mirelis, B; Prats, G; Rossi, V; Salvatori, E, 2006
)
2.5
"Prulifloxacin (PUFX) is a prodrug-type new quinolone antibiotic and immediately converted to an active metabolite, ulifloxacin (UFX). "( Transporter-mediated hepatic uptake of ulifloxacin, an active metabolite of a prodrug-type new quinolone antibiotic prulifloxacin, in rats.
Aoki, M; Iguchi, M; Kato, Y; Kurosawa, T; Shibasaki, S; Tsuji, A; Yagi, Y, 2007
)
1.99

Effects

Prulifloxacin has been successfully tested in Phase III randomized, controlled trials. Patients with acute exacerbations of chronic bronchitis, uncomplicated and complicated urinary tract infections and chronic bacterial prostatitis.

ExcerptReferenceRelevance
"Prulifloxacin has an acceptable toxicity profile, comparable to that of other fluoroquinolones, with gastric disturbances, diarrhea, nausea and skin rash of mild-to-moderate severity being the most frequent adverse events."( Prulifloxacin: clinical studies of a broad-spectrum quinolone agent.
Giannarini, G; Selli, C; Tascini, C, 2009
)
2.52
"Prulifloxacin has demonstrated in vitro activity against all these pathogens."( Prulifloxacin in the treatment of acute exacerbations of COPD in cigarette smokers.
Biscione, G; Cazzola, M; Crigna, G; Pasqua, F, 2008
)
2.51
"Prulifloxacin has been successfully tested in Phase III randomized, controlled trials including patients with acute exacerbations of chronic bronchitis, uncomplicated and complicated urinary tract infections, and chronic bacterial prostatitis."( Prulifloxacin: clinical studies of a broad-spectrum quinolone agent.
Giannarini, G; Selli, C; Tascini, C, 2009
)
2.52

Actions

Prulifloxacin did not increase revertant colonies significantly in any of the test strains with or without metabolic activation system (S9 mix)

ExcerptReferenceRelevance
"Prulifloxacin produced lower or equal MPC values than the other two fluoroquinolones (93.3% and 73.3% compared with levofloxacin and ciprofloxacin, respectively)."( In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Gualco, L; Marchese, A; Schito, AM; Schito, GC, 2007
)
1.38
"Prulifloxacin did not increase revertant colonies significantly in any of the test strains with or without metabolic activation system (S9 mix)."( [Mutagenicity studies of prulifloxacin (NM441) and the active metabolite (NM394)].
Ando, M; Iwakura, K; Kojima, M; Shindo, Y; Sumi, N; Tamura, H; Watanabe, M; Yamashita, Y, 1996
)
1.32

Toxicity

Prulifloxacin had no adverse effects on reproductive function of the parent animals, and also on development of the fetuses. It did not affect delivery and the number of live newborns and birth index.

ExcerptReferenceRelevance
" Prulifloxacin had no adverse effects on reproductive function of the parent animals, and also on development of the fetuses."( [Reproductive and developmental toxicity studies of prulifloxacin (NM441)(1)--A fertility study in rats by oral administration].
Fujii, S; Furukawa, S; Kikumori, M; Morinaga, T; Shindo, Y; Sumi, N; Watanabe, M; Yasuhira, K, 1996
)
1.45
" Prulifloxacin also did not affect delivery and the number of live newborns and birth index, or have any adverse effects on the postnatal development of the first generation offspring (F1) such as differentiation, functional development, emotionality, motor ability, learning ability or reproductive performance."( [Reproductive and developmental toxicity studies of prulifloxacin (NM441)(2)--A teratogenicity study in rats by oral administration].
Fujii, S; Furukawa, S; Kikumori, M; Morinaga, T; Shindo, Y; Sumi, N; Watanabe, M; Yasuhira, K, 1996
)
1.45
" Prulifloxacin also did not affect the number of live newborns and birth index, and have any adverse effects on the postnatal development of the first generation offspring (F1) such as differentiation, functional development, emotionality, motor ability, learning ability and reproductive performance."( [Reproductive and developmental toxicity studies of prulifloxacin (NM441)(4)--A perinatal and postnatal study in rats by oral administration].
Fujii, S; Kikumori, M; Morinaga, T; Nishimori, T; Okazaki, I; Shindo, Y; Sumi, N; Watanabe, M, 1996
)
1.45
" Adverse events (AEs) were self-recorded by the patients after each instillation and classified by the investigator according to a classification grid considering account duration and intensity."( Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?
Autorino, R; Azzarito, G; Damiano, R; De Sio, M; Di Lorenzo, G; Giugliano, F; Palumbo, IM; Perdonà, S; Quarto, G, 2009
)
0.64
" BCG toxicity and local tolerability were evaluated by self-administered EORTC QLQ-BLS24 questionnaire, and BCG adverse events (AEs) were classified according a four-class classification."( [Prevention of topic toxicity of BCG with single-dose prulifloxacin. Preliminary results of a randomized pilot study].
Allegro, R; Billone, V; Giaimo, R; Melloni, D; Ruggirello, A; Serretta, V; Sommatino, F,
)
0.38
" Systemic class IIB and III adverse events occurred in only 14."( [Prevention of topic toxicity of BCG with single-dose prulifloxacin. Preliminary results of a randomized pilot study].
Allegro, R; Billone, V; Giaimo, R; Melloni, D; Ruggirello, A; Serretta, V; Sommatino, F,
)
0.38
" These findings help in management of prulifloxacin induced adverse effects by appropriate dose selection in clinical practice."( Correlation among the toxicity profiling (28-days repeated oral dose toxicity), toxicokinetics and tissue distribution data of ulifloxacin, the active metabolite of prulifloxacin in Wistar albino rats.
Das, AK; Nandi, U; Pal, TK; Roy, B, 2012
)
0.85

Pharmacokinetics

ExcerptReferenceRelevance
" The Cmax, AUC, and urinary excretion rates were not altered by food intake, whereas the Tmax was prolonged slightly."( Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers.
Kosuge, K; Morino, A; Nakashima, M; Okuyama, Y; Ozaki, M; Takebe, Y; Uematsu, T, 1994
)
0.29
"The pharmacokinetic properties and tolerability of three different strengths of prulifloxacin (CAS 123447-62-1), a new antibacterial agent prodrug of AF3013 (CAS 112984-60-8), have been investigated in a randomized, cross-over study performed in 12 Caucasian male subjects (age range 19-34 years)."( Pharmacokinetics and tolerability of prulifloxacin after single oral administration.
Brion, N; Dionisio, P; Gualano, V; Marchetti, M; Millérioux, L; Picollo, R; Rosignoli, MT, 2003
)
0.82

Bioavailability

ExcerptReferenceRelevance
" To increase the bioavailability of NM394, various prodrugs were synthesized and tested."( In vivo antibacterial activity of a prodrug of NM394, a thiazetoquinoline carboxylic acid derivative.
Kise, M; Kitano, M; Matsuda, M; Nishino, T; Ozaki, M; Segawa, J; Tomii, Y,
)
0.13
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Prulifloxacin, a broad-spectrum quinolone antibiotic, exhibits three distinct crystal forms, each with different bioavailability and therapeutic properties."( Quantitative study of ternary polycrystalline mixtures of prulifloxacin based on Raman spectra and Raman imaging maps.
Chen, J; Huang, Y; Li, X; Yu, Y; Zhang, L; Zhou, Y, 2024
)
3.13

Dosage Studied

ExcerptRelevanceReference
"2%, respectively within 72 hours after dosing of 400 mg."( Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers.
Kosuge, K; Morino, A; Nakashima, M; Okuyama, Y; Ozaki, M; Takebe, Y; Uematsu, T, 1994
)
0.29
" At 500 mg/kg, vomiting was observed every day or intermittently throughout the dosing period and salivation was observed almost every day from day 6 to the end of the dosing onward."( [Single and 4-week oral toxicity studies of prulifloxacin (NM441) in aged dogs].
Akune, A; Asaoka, H; Chihaya, Y; Ihara, T; Nagata, R; Nakama, K; Shindo, Y; Sumi, N, 1996
)
0.56
" No effects caused by the repeated dosing were seen in the plasma concentrations."( [A 4-week oral toxicity study of prulifloxacin (NM441) in rats followed by a 4-week recovery test].
Fukuda, K; Iwakura, K; Nishimura, N; Shindo, Y; Sumi, N; Tamura, K; Yamazaki, S, 1996
)
0.58
" No effects caused by the repeated dosing were seen in the plasma concentrations."( [A 4-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 4-week recovery test].
Ide, M; Iwakura, K; Nagatani, M; Oda, S; Shindo, Y; Sumi, N; Tamura, K, 1996
)
0.58
"Quinolones, an expanding class of clinically established potent antibiotics, is not freely soluble in water which prevents the design of liquid dosage forms and restricts their use in topical applications."( Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro study.
Cheng, Y; Fang, Y; Ma, M; Qu, H; Xu, P; Xu, T; Xu, Z, 2007
)
0.34
" At baseline and days 1 and 5, three 12-lead digital ECGs were recorded before and up to 24 hours after dosing at nine predefined timepoints."( Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study.
Di Loreto, G; Dionisio, P; Rosignoli, MT, 2010
)
0.75
" The last dosing was scheduled from 2 to 12 hours from tissue and plasma sampling."( Penetration of prulifloxacin into sinus mucosa of patients undergoing paranasal sinus elective endoscopic surgery.
Bellussi, L; De Benedetto, M; Dionisio, P; Passali, D; Picollo, R; Rosignoli, MT; Ruggieri, A; Tomacelli, G, 2012
)
0.73
" Ulifloxacin T(1/2) and plasma and tissue concentrations including the nose-paranasal sinuses mucosa allow once daily administration at the dosage of 600 mg."( Role of prulifloxacin in the treatment of acute rhinosinusitis.
Bellussi, LM; Crisanti, A; Passali, D, 2015
)
0.85
" The amount of ulifloxacin excreted in urine over a 24-h dosing period was similar in subjects with normal renal function and patients with mild impaired renal function, but lower in those with moderate and severe renal impairment."( New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment.
Ammendola, M; Comandini, A; Coppola, P; Del Vecchio, A; Di Loreto, G; Garofolo, F; Picollo, R; Tellone, V; Tongiani, S, 2018
)
0.71
"Our data show that prulifloxacin is a safe quinolone and is well tolerated in both subjects with normal renal function and patients with impaired renal function, requiring a minimal dosage adjustment only in patients with severe renal impairment."( New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment.
Ammendola, M; Comandini, A; Coppola, P; Del Vecchio, A; Di Loreto, G; Garofolo, F; Picollo, R; Tellone, V; Tongiani, S, 2018
)
1.04
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
quinolone antibioticAn organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.
fluoroquinolone antibioticAn organonitrogen heterocyclic antibiotic containing a quinolone (or quinolone-like) moiety and which have a fluorine atom attached to the central ring system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SMAD family member 2Homo sapiens (human)Potency8.48520.173734.304761.8120AID1346859
USP1 protein, partialHomo sapiens (human)Potency63.09570.031637.5844354.8130AID504865
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
SMAD family member 3Homo sapiens (human)Potency8.48520.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency10.01500.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency10.79090.000221.22318,912.5098AID743036; AID743040; AID743042; AID743053; AID743054
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency17.45490.001022.650876.6163AID1224838; AID1224893
EWS/FLI fusion proteinHomo sapiens (human)Potency11.77040.001310.157742.8575AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency11.19100.000214.376460.0339AID720691; AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency18.73160.000229.305416,493.5996AID743075; AID743077; AID743079
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.37580.001723.839378.1014AID743083
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency50.11870.354828.065989.1251AID504847
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency33.49150.000323.4451159.6830AID743065; AID743067
lamin isoform A-delta10Homo sapiens (human)Potency12.58930.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (59)

Assay IDTitleYearJournalArticle
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID117094Lethal dose on systemic infections in mice after oral administration1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID114659Compound was evaluated for oral efficacy on systemic infections in mice by Escherichia coli KC-141992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID114660Compound was evaluated for oral Pseudomonas aeruginosa E-21992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (118)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's27 (22.88)18.2507
2000's49 (41.53)29.6817
2010's31 (26.27)24.3611
2020's11 (9.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 51.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index51.41 (24.57)
Research Supply Index5.06 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index80.61 (26.88)
Search Engine Supply Index1.99 (0.95)

This Compound (51.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials31 (24.80%)5.53%
Reviews7 (5.60%)6.00%
Case Studies3 (2.40%)4.05%
Observational1 (0.80%)0.25%
Other83 (66.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of Prulifloxacin vs Phosphomycin in the Prophylasy of Urinary Tract Infection [NCT01231737]Phase 296 participants (Anticipated)Interventional2010-11-30Enrolling by invitation
Evaluation of the Efficacy and Safety of Prulifloxacin vs Levofloxacin in the Treatment of Chronic Bacterial Prostatitis. [NCT03201796]Phase 2168 participants (Actual)Interventional2016-02-02Completed
A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as [NCT02439632]Phase 3216 participants (Anticipated)Interventional2014-02-28Completed
A Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Prulifloxacin Versus Placebo in the Treatment of Acute Gastroenteritis in Adult Travelers [NCT00448422]Phase 3268 participants (Actual)Interventional2006-12-31Completed
A Multicenter, Double-Blind, Randomized Study to Compare The Safety and Efficacy of Prulifloxacin Versus Placebo in the Treatment of Acute Gastroenteritis in Adult Travelers [NCT00392574]Phase 3282 participants (Actual)Interventional2006-08-31Completed
[NCT02157571]Phase 3360 participants (Anticipated)Interventional2013-06-30Recruiting
A Randomized, Controlled, Single-blind, Parallel-group Comparison Between Levofloxacin and Prulifloxacin, in Patients With Acute Exacerbation of COPD Unresponsive to Other Antibiotics and Admitted to the Internal Medicine [NCT01710488]Phase 4258 participants (Actual)Interventional2009-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]